Pharmaceutical

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Non-Hodgkin Lymphoma: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Non-Hodgkin Lymphoma.

Apr 19, 2024 - 00:00
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Non-Hodgkin Lymphoma.
Read the original article

Tags:

Previous Article

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Small-Cell Lung Cancer: ...

Next Article

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Melanoma: Likelihood of ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Alvotech and Dr Reddy’s partner to commercialise AVT03

Alvotech and Dr Reddy’s partner to commercialise AVT03

May 23, 2024

Chronic fatigue syndrome estimated to affect 3.3 million in U.S., more than previously thought: CDC

Chronic fatigue syndrome estimated to affect 3.3 millio...

Dec 9, 2023

STAT+: Congress targets reducing hospital outpatient payments in new bills

STAT+: Congress targets reducing hospital outpatient pa...

Apr 19, 2023